HealthCholesterol Drug Repatha Slashes Heart Attack Risk By 27 Percent But Disappoints Doctors And Investors Amgen's cholesterol-reducing drug Repatha reduced heart attack rate by 27 percent and stroke by 21 percent. Why are doctors and investors disappointed at the results of the drug's clinical trial?by Allan Adamson
Healthy Living/WellnessAmgen Cholesterol Drug Repatha Turned Down By UK Cost Watchdogby Rina Marie Doctor
Healthy Living/WellnessNew Cholesterol Drugs Are Too Expensive: Independent Study Concludesby Ted Ranosa
Healthy Living/WellnessFDA Gives Nod To Praluent: New Class Of Cholesterol-Lowering Drug Is Priceyby James Maynard
Healthy Living/WellnessFDA Panel Pushes For Approval Of Amgen's Cholesterol-Lowering Drug Repathaby Rina Marie Doctor
Snapdragon 8 Elite Is Qualcomm's Answer to Apple's A18 Pro, Apple Intelligence, But Can It Rise Above?